WCLC Preview: ADCs, Bispecifics And Other Targeted Therapies Command Attention

Longer-Term MARIPOSA Results For J&J’s EGFR Drug Combo

Highlights will include data for Summit/Akeso’s PD-L1/VEGF bispecific versus Keytruda, ADCs and DLL3-targeting drugs for SCLC, and agents against EGFR, HER2 and Trop-2 in NSCLC.

Holographic concept of lung cancer display, lung disease, treatment of lung cancer, lung illness
The WCLC starts on 7 September in San Diego • Source: Shutterstock

The International Association for the Study of Lung Cancer’s World Conference on Lung Cancer from 7 to 10 September in San Diego will showcase the increased focus on targeted therapies, including rising interest in bispecific T-cell engagers (BiTEs) and antibody-drug conjugates (ADCs), in lung cancers.

Key Takeaways
  • The World Conference on Lung Cancer (WCLC) meeting 7-10 September in San Diego will highlight new directions in treatment, including antibody-drug conjugates and bispecifics.

More from Clinical Trials

More from R&D